| SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids J Jansen, KC Reimer, JS Nagai, FS Varghese, GJ Overheul, M de Beer, ... Cell stem cell 29 (2), 217-231. e8, 2022 | 183 | 2022 |
| Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus MA Ansari, V Pedergnana, C LC Ip, A Magri, A Von Delft, D Bonsall, ... Nature genetics 49 (5), 666-673, 2017 | 126 | 2017 |
| Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells. ZN Pollock S, Nichita NB, Böhmer A, Radulescu C, Dwek RA Proc Natl Acad Sci U S A. 107, 2010 | 85* | 2010 |
| Chronic hepatitis C viral infection subverts vaccine‐induced T‐cell immunity in humans C Kelly, L Swadling, S Capone, A Brown, R Richardson, J Halliday, ... Hepatology 63 (5), 1455-1470, 2016 | 63 | 2016 |
| COVID moonshot: open science discovery of SARS-CoV-2 main protease inhibitors by combining crowdsourcing, high-throughput experiments, computational simulations, and machine … H Achdout, A Aimon, E Bar-David, GM Morris BioRxiv, 2020 | 49 | 2020 |
| Accelerating antiviral drug discovery: lessons from COVID-19 A von Delft, MD Hall, AD Kwong, LA Purcell, KS Saikatendu, U Schmitz, ... Nature Reviews Drug Discovery 22 (7), 585-603, 2023 | 48 | 2023 |
| The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes A von Delft, TA Donnison, J Lourenço, C Hutchings, CE Mullarkey, ... Vaccine 36 (2), 313-321, 2018 | 45 | 2018 |
| Highly-immunogenic virally-vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection L Swadling, J Halliday, C Kelly, A Brown, S Capone, MA Ansari, D Bonsall, ... Vaccines 4 (3), 27, 2016 | 40 | 2016 |
| The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design A Von Delft, IS Humphreys, A Brown, K Pfafferott, M Lucas, P Klenerman, ... Gut 65 (1), 112-123, 2016 | 39 | 2016 |
| Open Science Discovery of Potent Non-Covalent SARS-CoV-2 Main Protease Inhibitors COVID Moonshot Consortium, H Achdout, A Aimon, DS Alonzi, R Arbon, ... BioRxiv, 2020.10. 29.339317, 2020 | 38 | 2020 |
| A white-knuckle ride of open COVID drug discovery F von Delft, M Calmiano, J Chodera, E Griffen, A Lee, N London, ... Nature 594 (7863), 330-332, 2021 | 37 | 2021 |
| Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors ML Boby, D Fearon, M Ferla, M Filep, L Koekemoer, MC Robinson, ... Science 382 (6671), eabo7201, 2023 | 31 | 2023 |
| MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans I Esposito, P Cicconi, AM D’Alise, A Brown, M Esposito, L Swadling, ... Science translational medicine 12 (548), eaaz7715, 2020 | 28 | 2020 |
| ‘Favourable’ IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a … C Bucci, A von Delft, A Christian, VM Flemming, A Harrison, J Halliday, ... Journal of General Virology 94 (6), 1259-1265, 2013 | 27 | 2013 |
| HCV genotype-3a T cell immunity: specificity, function and impact of therapy IS Humphreys, A von Delft, A Brown, L Hibbert, JD Collier, GR Foster, ... Gut 61 (11), 1589-1599, 2012 | 27 | 2012 |
| Quantitative trait loci mapping of the mouse plasma proteome (pQTL) LM Holdt, A von Delft, A Nicolaou, S Baumann, M Kostrzewa, J Thiery, ... Genetics 193 (2), 601-608, 2013 | 25 | 2013 |
| Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes T Donnison, A von Delft, A Brown, L Swadling, C Hutchings, T Hanke, ... Vaccine 38 (32), 5036-5048, 2020 | 16 | 2020 |
| Kalirin as a novel treatment target for cognitive dysfunction in schizophrenia AW Mould, N Al-Juffali, A Von Delft, PE Brennan, EM Tunbridge CNS drugs 36 (1), 1-16, 2022 | 8 | 2022 |
| Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of … BJ Smilde, C Stockklausner, R Keen, A Whittaker, AN Bullock, A von Delft, ... BMC musculoskeletal disorders 23 (1), 519, 2022 | 6 | 2022 |
| Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses H Yang, A Llano, S Cedeno, A von Delft, A Corcuera, GM Gillespie, ... Cell Reports 35 (6), 2021 | 6 | 2021 |
